TheraRadar

Pharma Intelligence, Simplified

Landscape Oncology

Sarcoma

892 clinical trials

507 active
/
892 total (since 2015)
226
Phase 1 Active
435 total
324
Phase 2 Active
551 total
40
Phase 3 Active
62 total
6
Phase 4 Active
12 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Eli Lilly 3 6 3
Hansoh BioMedical R&D Company 3 0 0
Philogen S.p.A. 3 0 0
Pfizer 2 1 4
Amgen 2 0 0
USWM CT, LLC 2 0 0
Lantheus Medical Imaging 2 0 0
Inhibrx Biosciences, Inc 2 0 0
Jazz Pharmaceuticals 2 0 0
GI Innovation, Inc. 2 0 0
Novartis 1 2 1
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 1 0 3
MacroGenics 1 1 1
Takara Bio Inc. 1 1 0
PharmaMar 1 1 0
NCT04214067 ACTIVE NOT RECRUITING
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
National Cancer Institute (NCI) n=164
NCT05691478 RECRUITING
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
National Cancer Institute (NCI) n=1,122
NCT06422806 RECRUITING
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
National Cancer Institute (NCI) n=365
NCT03914612 ACTIVE NOT RECRUITING
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI) n=813
NCT02567435 ACTIVE NOT RECRUITING
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Cancer Institute (NCI) n=325
NCT05566795 RECRUITING
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
Day One Biopharmaceuticals, Inc. n=400
NCT05235165 RECRUITING
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Children's Oncology Group n=62
NCT03016819 RECRUITING
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
Advenchen Laboratories, LLC n=325
NCT05304585 RECRUITING
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Children's Oncology Group n=205
NCT07174427 RECRUITING
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
Takara Bio Inc. n=5
NCT06820957 ACTIVE NOT RECRUITING
Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body
Children's Oncology Group n=437
NCT04994132 ACTIVE NOT RECRUITING
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
Children's Oncology Group n=118
NCT05095376 ACTIVE NOT RECRUITING
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NRG Oncology n=265
NCT06088290 RECRUITING
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
PharmaMar n=450
NCT04307277 RECRUITING
Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma
Institut Claudius Regaud n=600
NCT06127407 RECRUITING
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC n=136
NCT05432791 ACTIVE NOT RECRUITING
Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
National Cancer Institute (NCI) n=73
NCT05411237 NOT YET RECRUITING
Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma
AIDS Malignancy Consortium n=130
NCT03651206 RECRUITING
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
ARCAGY/ GINECO GROUP n=138
NCT03422198 RECRUITING
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
University of Utah n=188
NCT03784014 ACTIVE NOT RECRUITING
Molecular Profiling of Advanced Soft-tissue Sarcomas
Institut National de la Santé Et de la Recherche Médicale, France n=603
NCT06988475 RECRUITING
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
Cancer Research UK n=30
NCT05646316 RECRUITING
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
NRG Oncology n=428
NCT03805022 RECRUITING
Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas
Institut Bergonié n=351
NCT06263231 ACTIVE NOT RECRUITING
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
Intensity Therapeutics, Inc. n=333
NCT05712694 RECRUITING
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Polaris Group n=300
NCT06332274 RECRUITING
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
Gustave Roussy, Cancer Campus, Grand Paris n=717
NCT06935409 NOT YET RECRUITING
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
Hansoh BioMedical R&D Company n=117
NCT05597917 RECRUITING
tTF-NGR Randomized Study - STS
Universität Münster n=126
NCT04757337 RECRUITING
Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients
UNICANCER n=214
NCT02413736 ACTIVE NOT RECRUITING
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
Heikki Joensuu n=255
NCT06836492 RECRUITING
A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.
Yizhuo Zhang n=300
NCT04031677 RECRUITING
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC n=250
NCT04967521 ACTIVE NOT RECRUITING
SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma
Sarcoma Alliance for Research through Collaboration n=108
NCT06669013 RECRUITING
Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas
N.N. Petrov National Medical Research Center of Oncology n=40
NCT06480396 NOT YET RECRUITING
High Versus Lower Intensity Surveillance Following Resection of Retroperitoneal Sarcoma
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano n=584
NCT04650984 RECRUITING
A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Philogen S.p.A. n=102
NCT05057130 RECRUITING
Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors
Blokhin's Russian Cancer Research Center n=50
NCT02565498 ACTIVE NOT RECRUITING
Preoperative vs Postoperative IMRT for Extremity/Truncal STS
Mount Sinai Hospital, Canada n=210
NCT05328258 RECRUITING
Use of GnRHa During Chemotherapy for Fertility Protection
Kenny Rodriguez-Wallberg n=500
NCT04396860 COMPLETED
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
National Cancer Institute (NCI) n=159
NCT05218499 COMPLETED
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Boehringer Ingelheim n=400
NCT06058793 COMPLETED
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
Boehringer Ingelheim n=138
NCT02451943 COMPLETED
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Eli Lilly and Company n=509
NCT05269355 TERMINATED
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
PTC Therapeutics n=359
NCT04979442 TERMINATED
Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma
Rain Oncology Inc n=175
NCT04963517 COMPLETED
Exercise Intervention for Bone Tumor Patients
Universität Duisburg-Essen n=11
NCT06370871 WITHDRAWN
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
Boehringer Ingelheim
NCT04656262 TERMINATED
Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients
Istituto Oncologico Veneto IRCCS n=79
NCT04780464 TERMINATED
A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC n=14
NCT05024253 COMPLETED
Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements.
Children's Cancer Hospital Egypt 57357 n=48
NCT02573324 COMPLETED
A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
AbbVie n=691
NCT03495921 TERMINATED
A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
Gradalis, Inc. n=32
NCT02606461 COMPLETED
Selinexor in Advanced Liposarcoma
Karyopharm Therapeutics Inc n=342
NCT02997358 COMPLETED
Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma
Gustave Roussy, Cancer Campus, Grand Paris n=150
NCT02379845 COMPLETED
NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall
Nanobiotix n=180
NCT02929394 TERMINATED
Trabectedin Maintenance Post 1st-line in STS
European Organisation for Research and Treatment of Cancer - EORTC n=13
NCT02979899 COMPLETED
Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma
Tracon Pharmaceuticals Inc. n=128
NCT03520959 TERMINATED
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=1
NCT03773510 WITHDRAWN
Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin
Italian Sarcoma Group
NCT02672527 COMPLETED
Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma
Gustave Roussy, Cancer Campus, Grand Paris n=103
NCT02711007 COMPLETED
Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy
GUO WEI n=37